- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Peter Jørgensen: Patient Engagement on Biosimilars
Peter Jørgensen, director of the Industrial Association for Generic and Biosimilar Medicines, Denmark, explains how Denmark has engaged with patients on biosimilars.
Transcript
What we have done in Denmark is, actually, we have taken the patients onboard. In the decision-making process, we have developed information for patients, which has been done by the authorities, not by companies, but by the authorities in cooperation with the patients. They have not been able to dictate the contents, but their concerns and their questions have been taken into consideration and have been answered.
If you look, for instance, at the website of the Danish Medicines Agency, you will see some very convincing “yes” answers or “no” answers to some of the most normal questions that patients might have about biosimilars.
But I think the main thing is to explain to people that, no, you’re not getting a new treatment. You’re not getting a new product. You’re simply getting another producer at a much lower price. It’s not a new treatment. It’s not really switching in the sense where we normally use that word.
Language is of course important. It’s very, if you will, uphill to try to change people’s perception of language and what you interpret when you use special words. That is also true in this area.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Q&A: Dr Kimberly Maxfield Explains How BsUFA III Will Advance the US Biosimilar Industry
December 20th 2023At AMCP Nexus, Kimberly Maxfield, PhD, pharmacologist at the FDA, delved into how the third reauthorization of the Biosimilar User Fee Act (BsUFA III) will shape the American biosimilar market and improve development efficiency over the next few years.
